LT3063139T - Heterociklinis junginys - Google Patents

Heterociklinis junginys

Info

Publication number
LT3063139T
LT3063139T LTEP14800152.2T LT14800152T LT3063139T LT 3063139 T LT3063139 T LT 3063139T LT 14800152 T LT14800152 T LT 14800152T LT 3063139 T LT3063139 T LT 3063139T
Authority
LT
Lithuania
Prior art keywords
heterocyclic compound
heterocyclic
compound
Prior art date
Application number
LTEP14800152.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Shizuo Kasai
Takashi Nakahata
Asato Kina
Hideki Hirose
Takeshi Yamasaki
Tohru Yamashita
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of LT3063139T publication Critical patent/LT3063139T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
LTEP14800152.2T 2013-10-29 2014-10-28 Heterociklinis junginys LT3063139T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013224093 2013-10-29
PCT/JP2014/005438 WO2015064083A1 (en) 2013-10-29 2014-10-28 Heterocyclic compound

Publications (1)

Publication Number Publication Date
LT3063139T true LT3063139T (lt) 2019-02-25

Family

ID=51932560

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14800152.2T LT3063139T (lt) 2013-10-29 2014-10-28 Heterociklinis junginys

Country Status (19)

Country Link
US (1) US9120777B2 (https=)
EP (1) EP3063139B1 (https=)
JP (1) JP6450755B2 (https=)
AR (2) AR098215A1 (https=)
CY (1) CY1121279T1 (https=)
DK (1) DK3063139T3 (https=)
ES (1) ES2710657T3 (https=)
HR (1) HRP20190133T1 (https=)
HU (1) HUE041792T2 (https=)
LT (1) LT3063139T (https=)
PL (1) PL3063139T3 (https=)
PT (1) PT3063139T (https=)
RS (1) RS58321B1 (https=)
SI (1) SI3063139T1 (https=)
SM (1) SMT201900101T1 (https=)
TR (1) TR201901986T4 (https=)
TW (1) TWI668214B (https=)
UY (1) UY35801A (https=)
WO (1) WO2015064083A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6121339B2 (ja) * 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
CN114981260A (zh) * 2019-12-19 2022-08-30 斯特拉斯堡大学 σ-1受体配体及其用途
CN116368140A (zh) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
KR20060123292A (ko) 2003-11-10 2006-12-01 쉐링 악티엔게젤샤프트 Ccr-5 길항제로서 유용한 벤질에테르 아민 화합물
WO2008019967A2 (en) * 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
JP2012526136A (ja) 2009-05-07 2012-10-25 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物として有用な置換スピロ環式アミン
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用

Also Published As

Publication number Publication date
US9120777B2 (en) 2015-09-01
TR201901986T4 (tr) 2019-03-21
AR098215A1 (es) 2016-05-18
AR128158A2 (es) 2024-03-27
WO2015064083A1 (en) 2015-05-07
PT3063139T (pt) 2019-02-22
TWI668214B (zh) 2019-08-11
RS58321B1 (sr) 2019-03-29
HRP20190133T1 (hr) 2019-03-22
EP3063139B1 (en) 2018-11-21
SMT201900101T1 (it) 2019-02-28
DK3063139T3 (en) 2019-03-11
JP2016535040A (ja) 2016-11-10
EP3063139A1 (en) 2016-09-07
HUE041792T2 (hu) 2019-05-28
US20150119412A1 (en) 2015-04-30
JP6450755B2 (ja) 2019-01-09
UY35801A (es) 2015-06-30
ES2710657T3 (es) 2019-04-26
CY1121279T1 (el) 2020-05-29
PL3063139T3 (pl) 2019-05-31
SI3063139T1 (sl) 2019-03-29
TW201542539A (zh) 2015-11-16

Similar Documents

Publication Publication Date Title
IL249518B (en) A compound that inhibits trk
EP3026051A4 (en) Heterocyclic compound
GB201311891D0 (en) Novel compound
EP3029031A4 (en) Heterocyclic compound
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
SG11201600759XA (en) Novel quinoline-substituted compound
GB201302368D0 (en) Compound
IL245301A0 (en) New heterocyclic compounds
ZA201507044B (en) Pyridinylpyrazoloquinoline compound
EP2975031A4 (en) Heterocyclic compound
EP3061754A4 (en) Heterocyclic compound
HUE041792T2 (hu) Heterociklusos vegyület
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
IL241962B (en) Heterocyclic acetamide compound
EP2948457A4 (en) COMPOUNDS
GB201307331D0 (en) Compound
GB201408643D0 (en) Compound
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives